Cross-Sector entity
market-trends is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Arcturus Therapeutics, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Cross-Sector story that mention sa-mRNA, all published on March 2, 2026.
1 verified story tracked
Last mentioned: Mar 2, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Arcturus Therapeutics, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Cross-Sector story that mention sa-mRNA, all published on March 2, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering sa-mRNA. Shared-story counts are live from our verified record — not editorial picks.
Q4 Earnings Release
Both companies scheduled to report full-year 2025 financial results.
ARCT-032 Phase 1b
Arcturus releases positive interim data for Cystic Fibrosis candidate.
Kostaive Approval
Japan's MHLW approves the first sa-mRNA COVID-19 vaccine.
Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, with investors focusing on Arcturus's sa-mRNA commercialization and Rigel's path to sustained profitability. Both companies represent different archetypes of the biotech sector's shift toward commercial execution.
Source: Seeking Alpha · Seeking Alpha
